Seeking Alpha
News source@seekingalpha.com
Join Seeking Alpha, the largest investing community in the world. Get stock market news and analysis, investing ideas, earnings calls, charts and portfolio analysis tools.
Following
Followers
Posts
Replies
Highlights
Media
Likes
#AutonomousRobots #ArtificialIntelligence #Industry4.0
seekingalpha.com
CES 2026: AI And Robotics Shift From Hype To Deployment
Autonomous collaborative robots are increasingly emerging as core industrial infrastructure and moving from optional automation to essential components of modern factories, logistics networks, and construction environments.
#Tariffs #TradePolicy #GlobalEconomy
seekingalpha.com
A New Flashpoint In U.S./Europe Trade Relations
Europe faces an immediate shock via reduced export volumes to the U. S. , one of its most important external markets.
By Seema Shah, Chief Global Strategist
President Trump announced over the weekend that, beginning February 1, the U.
#GreenEconomy #SustainableInvestment #ClimateTransition
seekingalpha.com
Sustainable Investment: An Improving Context For 2026
The climate transition is contributing to growth in the wider green economy. The global green economy made up 8. 6% of listed equity markets, with a market capitalisation of US$7.
#Economy #Investment #LaborMarket
seekingalpha.com
Weekly Market Pulse: Central Planning Gone Awry
We are entering an age of scarcity. Our population is aging, prime working age labor participation is near an all-time high, and population growth this year will likely be nil if not outright negative due to current immigration policies.
#BabyBoomerInvesting #TargetDateFunds #RetirementPlanning
seekingalpha.com
100 Year Perspective Provides Prospective
I've released my new book: Fixing Target Date Funds. I'm president of Target Date Solutions, developer of the patented Safe Landing Glide Path, Soteria personalized target date accounts, and Age Sage do-it-yourself investing.
#Biotech #Pharmaceuticals #FDAApproval
seekingalpha.com
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug (NASDAQ:CORT)
CORT's strong balance sheet enables pursuit of additional clinical evidence to address the FDA's concerns and potentially secure Relacorilant approval.
#Biotech #Pharmaceuticals #FDAApproval
seekingalpha.com
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug (NASDAQ:CORT)
CORT's strong balance sheet enables pursuit of additional clinical evidence to address the FDA's concerns and potentially secure Relacorilant approval.
